Abbott India Ltd Company History

All shares issued to Boots Pure Drug Co., Ltd. Only 5 shares issued

for cash.

2,00,000 shares issued to the present Company.

The Company was incorporated on 15th December. The Company

Manufacture `Boots' brand of medical and pharmaceutical products and

agricultural and animal health products. The leading lines of

manufacture includes insulin injections, anti-dysentery drugs, vitamin

preparations, penicillin preparations, sulphonamide tablets, household

remedies, animal health products of Mindif series and agro-chemicals.

The plant with a licensed capacity of 1,500 mega units per annum was

commissioned in January. In September, a sterile manufacturing unit

for the vialling of insulin injections was commissioned.

On 19th October, the Company entered into a technical collaboration

agreement with Boots Pure Drug Co. Ltd., England for manufacturing

crystalline insulin and formulations thereof and agreed to pay to them

at the rate of 3% on the sale value of basic crystalline insulin used

in the manufacture of preparations thereof, subject to a maximum of

5,000 per annum.

In December, 2,00,000 shares issued to public (prem. Rs 13 per

shares).

25,000 shares issued at par to L.I.C., U.T.I. and I.C.I.C.I. on

conversion of 5% debenture holdings.

The name of the Company was changed from Boots Pure Drug Co. (India)

Ltd., to the present one from 1st November. The name was further

changed to Boots Pharmaceuticals Ltd., from 1st January.

25,000 shares issued at par to L.I.C., U.T.I. and I.C.I.C.I. on

conversion of 5% debenture holdings.

The Company undertook to set up a new chemical plant at Ahmednagar, a

backward area in Maharashtra, for the manufacture of Ibuprofen from the

basic stage in technical collaboration with its parent company.

Ibuprofen is a raw material of Boots original research.

7,75,000 Bonus shares issued in the proportion 1:1.

1,48,150 Right Equity shares issued to Indian shareholders (prem. Rs

3.50 per shares: prop. 2:9)

2,66,050 Bonus shares issued in prop. 1:3.

The Company issued 1,70,000-15% non-convertible debentures of Rs 100

each. These debentures were redeemed on 5th October, 1990 at a premium

of Rs 5 per debenture.

Boots Company PLC, England voluntarily decided to dilute its

shareholding in the Company by disinvesting 3,00,000 equity share of Rs

10 each at a premium of Rs 45 per share.

The Company also issued 4,27,290 No. of Equity shares of Rs 10 each

at a premium of Rs 45 per share as rights to resident Indian equity

shareholders.

Out of the total issue of 7,27,280 No. of equity share, 6,81,088

shares were offered as rights to shareholders other than Boots Company

PLC, England in the proportion 2:5. Only 6,12,031 shares were taken

up. Out of the remaining 46,192 shares, 36,364 shares were offered to

employees Including Indian working directors)/workers on equitable

basis and 9,828 shares were offered to business associates of the

Company. The unsubscribed portion of 69,057 shares of the

shareholder's quota were allotted to employees/workers of the Company.

The object of rights issue and offer for sale was to reduce the

holding of Boots Company PLC, England in the Company from 53% to 40%.

13,58,520 Bonus equity shares issued in prop. 3:5.

Applications were made to Government for expansion of capacity upto

200 tonnes per annum for Ibuprofen and an endorsement of capacity upto

300 M.U. for highly purified insulin.

4,27,280 new equity shares were offered as Rights to the resident

Indian equity shareholders at a premium of Rs 45 per shares.

The Company received a letter of intent for both the products and the

expansion capacity of Ibuprofen was being implemented.

An application was made for an industrial license to produce a bulk

drug, "Ranitidine Hydrochloride" and its formulations.

40,50,000 bonus equity shares issued in prop. 1:1.

`Advene' a new anti-peptic ulcerant and `Froben' a more potent

anti-rheumatic drug were launched.

The Company undertook a project to set up a new formulation factory

at Jejuri in Pune district.

A number of new products, namely Brufen Junior Syrup, Chota Strepsils

Icy, Optrex Eye Lotion, Highly Purified Insulins and Nausidome were

launched during the year.

A few new products like Human Insulin's, Frozen SR. and Optren Eye

Drops were launched during the year.

Products such as Novopen, Human mixtard, Mixtard penfills were

launched.

Beem Healthcare Ltd., Lenbrook Pharmaceuticals Ltd. and Valencia

Pharmaceuticals Ltd are the subsidiaries of the Company.

It is proposed to change the name of the company to Knoll

Pharceuticals Ltd. effective 31st October, name was changed to Knoll

Pharmaceuticals Ltd.

Clivarine, an anticoagulant low molecular weight heparin preparation

used for the prophylasix of deep vein thrombosis was launched.

The Company has acquired the product Epilex for a total consideration

of Rs 9.90 crores. The product is used in the treatment of epilepsy.

The new Goa plant of Knoll Pharmaceuticals, a part of the BASF group,

has been set up. BASF India has also set up two state-of-the-art

plants to manufacture speciality dyes and dispersons in Mangalore and

these were commissioned.

Knoll Pharma is currently the fifth-largest domestic formulations

company. It is likely to use the proceeds to acquire formulation

brands in the cardiovascular, antibiotic and neurology segments.

Lupharma GmbH, a wholly owned subsidiary of Knoll AG of Germany, is

making a public offer for the acquisition of a further 11 per cent

holding in Knoll Pharmaceuticals Ltd (KPL), the Indian arm of the

business.

Knoll India has recently entered into a co-marketing arrangement with

SmithKline Beecham Pharmaceuticals (India) for the latter's formulation

of amoxycillin and clavulanic acid.

Knoll India is to launch new products from the research pipelines of

both Knoll AG and the erstwhile Boots plc.

KPL launched an anticoagulant low molecular weight heparin

preparation - Cremaffin - used for the prophylaxis of deep vein

thrombosis.

Lupharma GmbH, a wholly-owned subsidiary of Knoll AG of Germany, had

made a public offer for acquisition of a further 11 per cent holding in

Knoll Pharmaceuticals in order to take its stake up to 51 per cent from

the current levels of 40 per cent.

Beem Healthcare which was engaged in marketing of consumer brands has

been merged with Knoll with effect with July 1998.

Knoll Pharma has entered into a three-way pact with the Gujarat-based

Torrent Pharmaceuticals and Danish giant, Novo Nordisk, in the

anti-diabetes (human insulin) segment.

The Company has entered into a agreement with Kalpataru Homes for the

assignment of the leasehold.

Ranbaxy Laboratories Ltd (RLL) has entered into an agreement with

Knoll Pharmaceuticals Ltd (KPL) to market the latter's leading brands

in select overseas markets.

Lupharma UK Holding One Ltd., a wholly-owned subsidiary of Lupharma

GmbH has proposed to acquire 82,62,000 shares i.e. 51 per cent of the

share capital of Knoll Pharmaceuticals from Lupharma Gmbh.

Knoll Pharmaceuticals, the maker of popular painkiller Brufen, has changed its name to Abbott India following global takeover of Knoll's majority stakeholder - German firm BASF Pharma - by US drug major Abbott Laboratories.

Mr V D Narkar, Director of Abbott India Ltd, has resigned with effect from June 19, 2003.

Mr.Ashok Dayal is appointed as Additional Director of the company.

Scheme of amalgamation of Lenbrook Pharmaceuticals (a wholly owned subsidiary of the company) with the company.

Abbott India Ltd has informed that the Board of Directors of the Company at its meeting held on February 14, 2008, has appointed Mr. Thomas Dee as the Additional Director of the Company.

Abbott India Ltd has recommended a dividend of Rs 14.00/- per share

Abbott India Ltd has recommended a dividend of Rs 17.00/- per share

Abbott India Ltd has recommended a dividend of Rs 17.00/- per share

Abbott India Ltd has recommended a dividend of Rs 17.00/- per share

Abbott has been named the ‘Multinational Pharmaceutical Company of the Year’ for the third consecutive year at the 2013 Frost & Sullivan India Healthcare Excellence Awards held in Mumbai.

Abbott India announced the national results from astudy assessing the prevalence of hypothyroidism in India that was published in the July 2013 issue of the Indian Journal of Endocrinology and Metabolism.

Abbott, one of the largest diversified global healthcare companies and the number one pharmaceutical company in India, in partnership with the Indian Thyroid Society (ITS), announced the launch of a thyroid awareness initiative in Uttar Pradesh and Uttarakhand.

Abbott was awarded the prestigious Golden Peacock Innovation Management Award at the

8th International Conference on Corporate Social Responsibility held in Bangalore.